Anti-Mouse F4/80 [Clone Cl:A3-1] — Biotin

Thioglycolate-induced peritoneal macrophages from C57BL/6 mice

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

Cl:A3-1 activity is directed against mouse F4/80.

Macrophages play an important role in innate and adaptive immune system functions¹. F4/80 antigen is a widely used cell-surface marker of murine macrophages^{1, 2} encoded by the Adgre1 locus³. F4/80 antigen is a G protein-coupled receptor with an extracellular domain containing repeated Epidermal Growth Factor-like calcium-binding domains and as such is a member of the EGF-TM7 protein family, which itself is a subfamily of the adhesion G protein-coupled receptors (ADGRE) family. F4/80 is thought to have dual adhesion and signaling functions due to its receptor domains and is known to be required for the differentiation of antigen-specific CD8⁺ T regulatory cells¹ . Adgre1 null mutant mice have a dysregulated autoimmune response and regulatory T cell generation³. Additionally, unstimulated resting macrophages express F4/80 at higher levels than activated macrophages¹.

Cl:A3-1 was generated by immunizing a rat with thioglycolate-induced peritoneal macrophages from C57BL/6 mice⁴. Spleen cells were fused with mouse myeloma cell line NS1. Cl:A3-1 does not bind to macrophages via Fc receptors and is not cytotoxic. Cl:A3-1 is able to modulate Listeria-induced cytokine signaling between macrophages and natural killer cells².

F4/80 is constitutively expressed on most macrophages, except those located in T cell areas and marginal zones of lymph nodes and spleen, as well as on some dendritic cells. Blood monocytes also express F4/80, but at low levels relative to mature macrophages.

N/A

1 Lin HH, Faunce DE, Stacey M, et al. J Exp Med. 201(10):1615-1625. 2005.
2 Warschkau H, Kiderlen AF. J Immunol. 163(6):3409-16. 1999.
3 Waddell LA, Lefevre L, Bush SJ, et al. Front Immunol. 9:2246. 2018.
4 Austyn JM, Gordon S. Eur J Immunol. 11(10):805-815. 1981.
5 Hume DA, Perry VH, Gordon S. Anat Rec. 210(3):503-512. 1984.
6 Perry VH, Hume DA, Gordon S. Neuroscience. 15(2):313-326. 1985.
7 Morris L, Graham CF, Gordon S. Development. 112(2):517-526. 1991.
8 Haidl ID, Jefferies WA. Eur J Immunol. 26(5):1139-1146. 1996.